Claims

1. Use of an extracellular matrix modulating agent in the manufacture of a medicament for the prevention and/or suppression of guttae formation~~treatment of Fuchs endothelial corneal dystrophy FECD by modulating the expression of extra- cellular matrix by corneal endothelial cells~~, wherein the agent comprises 1-(4-fluoro-5-iso quinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.

2. Use of an extracellular matrix modulating agent in the manufacture of a medicament for the prevention and/or suppression of the recurrence of guttae formation, wherein the agent comprises 1-(4-fluoro-5-iso quinolinesulfonyl)-2-methyl-1,4- homopiperazine or a salt thereof, or a solvate thereof.

~~2. The use according to claim 1, wherein the 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine is (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine.~~

~~3. The use according to claim 1 or claim 2, wherein the medicament is to prevent and/or suppress the guttae formation.~~

~~4. The use according to claim 1 or claim 2, wherein the medicament is to prevent and/or suppress the recurrence of the guttae formation.~~

3. The use according to claim 1 or claim 2, wherein the medicament is to be administered to a Fuchs endothelial corneal dystrophy (FECD) patient.

4. The use of claim 3, wherein the patient is an early stage FECD patient.

5. The use according to any one of the preceding claims ~~1 to 4~~, wherein the medicament is a liquid formulation.

6. The use according to any one of the preceding claims, wherein the medicament is an eye drop.

~~6. An extracellular matrix modulating agent for use in the treatment of a corneal disorder, by modulating the expression of extracellular matrix by corneal endothelial cells comprising 1 (4 fluoro 5 isoquinolinesulfonyl) 2 methyl 1,4 homopiperazine or a salt thereof, or a solvate thereof.~~